The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
Abstract
BACKGROUND: Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy. METHODS AND RESULTS: A post hoc analysis was performed that combined data from 2 prospective, randomized clinical trials in which 10,001 ("Treating to New Targets") and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering") patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. In models with LDL cholesterol, non-HDL cholesterol and apolipoprotein B were positively associated with cardiovascular outcome, whereas a positive relationship with LDL cholesterol was lost. In a model that contained non-HDL cholesterol and apolipoprotein B, neither was significant owing to collinearity. Total/HDL cholesterol ratio and the apolipoprotein B/A-I ratio in particular were each more closely associated with outcome than any of the individual proatherogenic lipoprotein parameters. CONCLUSIONS: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol. Inclusion of measurements of the antiatherogenic lipoprotein fraction further strengthened the relationships. These data support the use of non-HDL cholesterol or apolipoprotein B as novel treatment targets for statin therapy. Given the absence of interventions that have been proven to consistently reduce cardiovascular disease risk through raising plasma levels of HDL cholesterol or apolipoprotein A-I, it seems premature to consider the ratio variables as clinically useful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
(1996) · Cited by 6,884
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationGlobal Burden of Cardiovascular Diseases
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 3,014
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Cited by
Sorted by citations
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Gut Microbiome: Profound Implications for Diet and Disease
Hills, R. D., Pontefract, B., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,143
Metadata
- Authors
- Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., & Grundy, S. M.
- Affiliations
- State University of New York (US)
- From the Academic Medical Center, University of Amsterdam (J.J.P.K., W.A.v.d.S., S.M.B.), Amsterdam, the Netherlands; Center for Preventive Medicine, Ullevål University Hospital (I.H., T.R.P.), Oslo, Norway; Pfizer Inc (M.G., N.B.C., D.A.D., M.S.), New York, NY; the Heart Research Institute (P.B.), Sydney, Australia; Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine (P.D.), San Francisco, Calif; University Hospital (A.G.O.),...
- ORCID
- Venue
- Circulation
- Published
- 2008-06-10
- Volume
- 117
- Issue
- 23
- Pages
- 3002-3009
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1982036768
- Cited by
- 478
- References
- 45
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 16 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 23 · 2017: 25 · 2016: 14 · 2015: 32 · 2014: 23 · 2013: 36 · 2012: 31
- FWCI
- 52.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- statin therapy, non-HDL cholesterol, apolipoprotein B, apolipoprotein B/A-I ratio, TC/HDL-C ratio, LDL cholesterol, apolipoprotein A-I, cardiovascular events, coronary artery disease, lipid-lowering targets, lipoprotein ratios
- MeSH terms
- Aged, Apolipoproteins B, Coronary Disease, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Triglycerides, Proportional Hazards Models, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
